Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Research & Development (2017 - 2025)

Historic Research & Development for BioCorRx (BICX) over the last 9 years, with Q3 2025 value amounting to $1.0 million.

  • BioCorRx's Research & Development rose 11833.88% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 2968.36%. This contributed to the annual value of $1.5 million for FY2024, which is 6641.66% up from last year.
  • As of Q3 2025, BioCorRx's Research & Development stood at $1.0 million, which was up 11833.88% from $296860.0 recorded in Q2 2025.
  • In the past 5 years, BioCorRx's Research & Development registered a high of $1.0 million during Q3 2025, and its lowest value of $123262.0 during Q2 2021.
  • For the 5-year period, BioCorRx's Research & Development averaged around $363302.3, with its median value being $286962.0 (2023).
  • In the last 5 years, BioCorRx's Research & Development crashed by 9083.62% in 2021 and then soared by 21068.13% in 2022.
  • BioCorRx's Research & Development (Quarter) stood at $234423.0 in 2021, then skyrocketed by 128.69% to $536104.0 in 2022, then plummeted by 76.07% to $128295.0 in 2023, then skyrocketed by 112.43% to $272543.0 in 2024, then skyrocketed by 268.62% to $1.0 million in 2025.
  • Its Research & Development was $1.0 million in Q3 2025, compared to $296860.0 in Q2 2025 and $161919.0 in Q1 2025.